Suprafenid, containing the active ingredient Ketoprofen, is a Nonsteroidal Anti-inflammatory Drug (NSAID) used to relieve symptoms related to inflammatory or irritative states. It is commonly applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to pain, inflammation, stiffness, and fever.

Suprafenid is generally used in conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout flares, and primary dysmenorrhea. It is also relevant for easing symptoms following musculoskeletal trauma like sprains and strains, and in postoperative or post-dental extraction scenarios. The medication helps moderate the distressing manifestations of these conditions, supporting functional stability. This supportive relief contributes to easing the overall symptom load during difficult episodes.

---

Quick Fact: Relief for Joint Stiffness and Pain

Suprafenid is commonly used across conditions presenting with acute or chronic pain and inflammatory processes. In chronic joint conditions, it contributes to easing the impact of symptoms on functional stability, and during acute episodes, it supports patients during episodes of heightened discomfort.

Regulatory References

1. Ketoprofen: MedlinePlus Drug Information

Suprafenid is a medicine available for use by adult patients who do not have specific contraindications documented in official regulatory labeling. These documents establish strict rules for who must not take the medicine.

Contraindicated Populations (Must Not Use)

Official regulatory documents define the following strict exclusions for Suprafenid use:

• Prior Hypersensitivity: Individuals with a history of asthma, hives (urticaria), or allergic-type reactions after taking Suprafenid, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
• Cardiovascular Disease: Patients with established severe heart failure (e.g., NYHA class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Gastrointestinal History: Patients with active or a history of recurrent peptic ulceration, bleeding, or perforation.
• Organ Impairment: Those with severe and advanced renal impairment or hepatic failure.
• Surgical Context: Use for the treatment of pain in the setting of coronary artery bypass graft (CABG) surgery is prohibited.

Use Restrictions

• Age-Related Eligibility: Safety and efficacy have not been established for pediatric patients. Use is generally not recommended for children under a specified age (e.g., 16 or 18 years).
• Pregnancy and Lactation: The medicine is contraindicated during the third trimester of pregnancy. Use is not recommended during the second trimester (after 20 weeks gestation) or while breastfeeding.

Interactions with other medicines and products

Suprafenid, containing Ketoprofen, has officially documented interaction restrictions governed by regulatory authorities.

Contraindicated Combinations

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including therapeutic doses of Aspirin, is strictly contraindicated due to a significantly increased risk of serious gastrointestinal adverse events, such as bleeding and ulceration. The medication is also prohibited for managing perioperative pain following coronary artery bypass graft (CABG) surgery, owing to the documented risk of cardiovascular thrombotic events.

Clinically Significant Pharmacodynamic and Pharmacokinetic Interactions

Interactions that amplify risk or alter drug levels are formally documented. Concurrent use with Anticoagulants (e.g., Warfarin), Oral Corticosteroids, and SSRIs increases the risk of bleeding. Pharmacodynamically, combining Ketoprofen with Diuretics or ACE Inhibitors may diminish the antihypertensive and natriuretic effects while increasing the risk of renal failure and hyperkalemia. Agents like Probenecid and Lithium are known to cause exposure modification; Probenecid reduces Ketoprofen clearance, and Ketoprofen reduces Lithium clearance, potentially leading to elevated plasma levels of both co-administered drugs.

Substance and Population Restrictions

Consumption of Alcohol or specific Herbal Products (e.g., Ginkgo) is documented to increase the overall risk of bleeding. In cases of renal impairment, there is an official caution regarding the potential accumulation of Ketoprofen metabolites.

How Suprafenid Works

Suprafenid's primary mechanism involves the inhibition of Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and COX-2. These enzymes are key components in the arachidonic acid cascade responsible for synthesizing pro-inflammatory signaling molecules called prostaglandins. By blocking this enzymatic step, the drug limits the generation of these mediators, contributing to a reduction in systemic and peripheral inflammatory processes and a decrease in the production of pyretic mediators.

Simultaneously, the drug acts as a modulator within the central nervous system (CNS). It engages specific neurotransmitter systems, such as the serotonergic system, to affect neural activity. This modulation directly influences the transmission of nociceptive signals within the CNS. The drug also exerts a suppressive effect on the parallel Lipoxygenase (LOX) pathway, reducing the formation of leukotrienes and further affecting the overall level of mediator-driven physiological response.

Suprafenid (Ketoprofen) is administered through multiple routes. For systemic effects, it is available as oral immediate-release (IR) and extended-release (ER) capsules. It can also be administered topically as a gel for localized relief or via parenteral injection (intravenous or intramuscular) in certain acute, supervised scenarios.

The dosage and frequency are determined by the specific formulation. Immediate-release capsules are typically taken multiple times a day (TID or QID), with a maximum recommended daily limit of 300 mg. In contrast, the 200 mg extended-release capsule is administered once daily and is not recommended for acute pain. When taking oral formulations, the capsule may be administered with food, milk, or an antacid to minimize potential gastrointestinal discomfort.

Specific administration rules apply to ensure proper use. A standard principle is utilizing the lowest effective dose for the shortest duration necessary. A key consideration for usage is population-specific dose adjustment: a lower starting dose must be initiated for older adults and individuals with reduced renal or hepatic function, reflecting recommended maximum dose limits. For topical application, the gel must be applied with gentle massage into the affected area, followed by thorough hand washing. If a dose is missed, instructions are to skip the dose if it is close to the next scheduled time, and never take a double dose.

Suprafenid: Recent Clinical Evidence

Clinical research has evaluated Suprafenid (a hypothetical drug with characteristics similar to NSAIDs) for managing acute and chronic pain associated with conditions such as osteoarthritis, rheumatoid arthritis, and postoperative recovery. Studies have aimed to determine its effectiveness, safety, and role in multimodal pain management strategies.

---

Key Findings from Clinical Trials

Area of Investigation	Study Findings Reported
Acute Pain (e.g., post-surgery, soft tissue injury)	Randomized controlled trials investigated pain relief compared to placebo or other analgesics, reporting observed changes in patient-rated pain intensity and overall relief scores. Some evidence suggested reduced reliance on opioid consumption when included in a pain management strategy.
Chronic Pain (e.g., Osteoarthritis)	Studies explored the effects on pain, stiffness, and joint function, often measured using validated assessment tools. Research examined outcomes over observation periods ranging from a few weeks to several months.

---

Safety and Tolerability Profile

Suprafenid’s safety profile, consistent with its drug class, has been a key focus of clinical monitoring. Gastrointestinal (GI) and renal function-related adverse events were monitored across various patient populations, particularly in long-term use studies. Research involving both oral and topical formulations showed that adverse events were generally mild to moderate in severity, with GI disturbances being among the most frequently observed. Certain patient groups, such as those with pre-existing renal conditions or a history of GI ulceration, were often excluded from study enrollment or closely monitored due to established risks associated with this drug class.

Common questions about Suprafenid (FAQ)

Q: How quickly should I expect to feel the effects of Suprafenid after taking it?

According to official product information, some patients who take the immediate-release (IR) capsules may begin to feel pain relief within 30 minutes. Peak concentrations in the bloodstream are typically reached between 0.5 and 2 hours for the immediate-release formulation.

---

Q: What are the most commonly reported side effects when first starting Suprafenid?

Regulatory documents indicate that the most commonly reported side effects are related to the gastrointestinal system, such as nausea, indigestion (dyspepsia), and abdominal pain. Central nervous system effects like headache, dizziness, and drowsiness are also frequently noted in clinical studies.

---

Q: Can Suprafenid cause stomach upset or digestive issues?

Yes, official safety information states that Gastrointestinal Disorders are among the most common adverse reactions. This can include general digestive issues such as stomach upset, nausea, and pain in the abdomen.

---

Q: Is it normal to feel a bit dizzy or lightheaded after taking Suprafenid?

Official information confirms that dizziness and somnolence (drowsiness) are reported as Common side effects. These effects are reported as a known and common possibility in official product information.

---

Q: How long do the mild side effects of Suprafenid usually last?

Clinical safety profiles indicate that any adverse events observed in trials are generally mild to moderate in severity. However, official documents do not specify a fixed timeframe for how long these mild effects may last.

---

Q: What does the package insert say about taking Suprafenid with fever reducers?

Official labeling strictly contraindicates (prohibits) co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes therapeutic doses of Aspirin. Patients are advised to consult a healthcare provider regarding the co-administration of Suprafenid with any other fever-reducing medicine.

---

Q: Is it safe to drive or operate machinery while taking Suprafenid?

Since common central nervous system side effects include dizziness and somnolence (drowsiness), caution is warranted. Due to the possibility of these common side effects, individuals engaging in activities requiring full alertness should exercise caution.

---

Q: Can children or teenagers be prescribed Suprafenid?

Regulatory documents state that the safety and effectiveness of this medication have not been established for use in pediatric patients. Decisions regarding its use in minors should be made by a qualified healthcare professional, as safety and effectiveness are not established.

---

Q: Why do some people say Suprafenid made them feel a little tired?

The official safety profile lists somnolence (drowsiness) as a common central nervous system (CNS) side effect. This is the physiological effect that may cause people to feel tired or sleepy after taking the medication.

---

Q: Can Suprafenid affect blood pressure or heart rate?

Yes, official warnings indicate that this class of medication can lead to the new onset of hypertension (high blood pressure) or worsen existing high blood pressure. Some patients may also experience an irregular, pounding, or racing heartbeat or pulse.

---

Q: Is there a known time of day that is best for taking Suprafenid?

While the immediate-release form can be taken multiple times per day, some clinical studies for the sustained-release form have suggested that evening administration may be preferred.

---

Q: What is the typical time frame for clinical trials involving Suprafenid?

Clinical trials for this drug have varied in length. Short-term studies, such as those lasting 2 to 14 days, assess acute pain relief. Longer observation periods, which can last several months or up to one year, are conducted for chronic conditions like arthritis.

---

Q: Can Suprafenid cause any issues with sleep patterns?

Yes, regulatory documents report that psychiatric adverse reactions can include insomnia (difficulty falling or staying asleep) and nightmares.

---

Q: Does Suprafenid have a risk of interacting with herbal remedies?

Official drug interaction warnings specify that the use of this drug with certain herbal products, such as Ginkgo, is documented to increase the overall risk of bleeding. Patients should consult their healthcare provider about combining the drug with any herbal supplements.

---

Q: Is there a generic version of Suprafenid available?

Yes, the active ingredient in Suprafenid, Ketoprofen, is available in generic immediate-release and extended-release capsule forms.

---

Q: How long before or after taking Suprafenid should I take a separate antacid?

Official prescribing information advises that the medication may be taken with food, milk, or an antacid to help reduce the potential for gastrointestinal discomfort. However, specific timing for taking a separate antacid dose is not provided in regulatory documents.

---

Q: Do clinical studies suggest Suprafenid works better for certain patient groups?

Official pharmacokinetic data indicates that the drug's clearance and unbound drug fraction are reduced in older adults. This difference in how the body processes the medication suggests that older patients may require a lower starting dose to manage their exposure.

---

Q: What is the difference between immediate-release and extended-release forms of Suprafenid?

The immediate-release (IR) form is designed to be taken multiple times a day for a rapid effect. In contrast, the extended-release (ER) form is taken once daily and is formulated for gradual absorption, maintaining consistent levels of the drug over a longer period.

---

Q: Is it possible to develop a tolerance to the effects of Suprafenid over time?

Regulatory warnings focus on the serious risks, such as cardiovascular and gastrointestinal events, which are known to increase with longer duration of use. Official labeling does not explicitly address the development of pharmacological tolerance (a reduced effect) over time.

---

Q: Can Suprafenid affect mood or cause emotional changes?

Yes, official safety information reports that psychiatric adverse reactions associated with the medication include depression, nervousness, insomnia, and general changes to mood.

---

Q: What is the 'half-life' of Suprafenid?

The reported elimination half-life for the immediate-release formulation is approximately 2 hours. This is the time it takes for the amount of drug in the body to be reduced by half. The half-life can be longer in certain patient populations, such as the elderly or those with reduced kidney function.

Storage Requirements

Suprafenid (Ketoprofen) must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F), with permissible excursions up to 30°C. The product must be protected from excessive heat, light, and moisture, and must be kept from freezing. The medication must remain in a tightly closed, light-resistant container. For safety, it is mandated to be stored out of the reach of children, utilizing a child-resistant closure.

Disposal Instructions

Official guidelines recommend disposing of unused or expired Suprafenid through a drug take-back program. As this medicine is not on the highly dangerous flush list, it must not be flushed down a toilet or poured into a drain. If a take-back program is unavailable, the product should be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a container before being placed in the household trash.